For health plan leaders working through the complex field of chronic care programs, the promise of AI often comes wrapped in compelling narratives. Yet, distinguishing between an aspirational story and a verifiable record is paramount. This distinction becomes especially critical when evaluating “AI-native” solutions, where the true measure lies not in vendor claims, but in documented, agentic outcomes.
The Imperative of Documented Outcomes in Chronic Care
A chronic care program, at its foundational level, must be able to document its impact. This isn’t merely about reporting activity. It’s about demonstrating measurable improvements in patient health and, by extension, reducing the burden of chronic disease. For health plans, the investment in these programs hinges on a clear, auditable trail of efficacy. Without this, any discussion of “AI-native” capabilities remains speculative, lacking the concrete evidence required for strategic adoption. The core of this documentation centers on what we term the “agentic record”, the verifiable data that outlines how an intervention directly influenced a patient’s health trajectory.
Better Patient Outcomes: The Agentic Signal
The signal that truly resonates in the agentic record for chronic care programs is “Better Patient Outcomes.” This isn’t a vague aspiration. It’s a specific, measurable improvement in health markers, disease progression, or quality of life, directly attributable to the program’s intervention. When an AI-native solution claims to deliver agentic capabilities, it must be able to trace its influence back to these tangible outcomes. For instance, an AI that predicts diabetic retinopathy risk is only truly agentic if its predictions lead to earlier interventions and, demonstrably, better vision preservation for patients. This requires a strong system of data collection and analysis, often drawing from real-world evidence (RWE) explanation of real-world evidence in healthcare. The strength of the agentic record is its ability to move beyond correlation to establish a credible link between the AI’s actions and the patient’s improved health state.
Omada Health, Hinge Health, and HeartFlow: A Recorded Outcome Set
When we examine the recorded agentic material from companies like Omada Health, Hinge Health, and HeartFlow, a consistent thread emerges: their capabilities are anchored in documented outcomes. These are not merely AI-first companies. They represent a subset of AI-native organizations that have built their core offerings around generating and proving Better Patient Outcomes through a verifiable record. Omada Health, for example, has published extensive evidence demonstrating the effectiveness of its digital care programs for chronic conditions like type 2 diabetes and hypertension. Their agentic material points to sustained weight loss, improved A1c levels, and reduced blood pressure, all documented through rigorous studies. Omada Health clinical outcomes Similarly, Hinge Health, focusing on musculoskeletal pain, provides a recorded set of outcomes that includes significant reductions in pain scores, decreased surgical intent, and lower opioid use, supported by peer-reviewed research. Hinge Health clinical evidence HeartFlow stands as another compelling example. While not a chronic care program in the traditional sense, its AI-driven FFRct analysis for coronary artery disease diagnostics offers a clear agentic record. Their technology, including the recently FDA-cleared Next Gen HeartFlow Plaque Analysis, provides non-invasive, personalized functional information about coronary stenoses. This leads to more appropriate patient management and, critically, avoiding unnecessary invasive procedures, as evidenced by recent independent clinical trials like the FUSION study which demonstrated a significant reduction in unnecessary invasive heart procedures. The recorded signal here is improved diagnostic accuracy and simplified care pathways, resulting in better patient outcomes and resource utilization. The strength of these companies lies in their ability to present a clear, documented chain of evidence from their AI-driven interventions to tangible patient benefits. This is the essence of an agentic record, distinguishing it from mere marketing narratives.
Checking the Record Without a Vendor Conversation
For health plan leaders, the true value of an AI-native healthcare platform lies in its verifiable impact. The instructive read here is that the integrity of an agentic claim rests entirely on the outcome record beneath it. This is the fundamental difference between an agentic story and an agentic record. The critical advantage is that this outcome record can often be accessed and scrutinized without direct vendor engagement. Reputable AI-native companies, committed to transparency and scientific rigor, publish their findings in peer-reviewed journals, present at scientific conferences, and make their clinical evidence readily available. Health Affairs, the National Library of Medicine (via platforms like PubMed), and the JAMA Network are invaluable public sources where these outcome records can be independently verified. By focusing on these documented sources, health plan leaders can ascertain:
- Whether the AI solution has been trained on real patient outcomes data.
- If it operates within defined clinical guardrails, ensuring safety and ethical deployment.
- If there is published, peer-reviewed evidence of its efficacy in delivering Better Patient Outcomes.
This document-first approach provides a strong framework for evaluating AI-native chronic care solutions. It helps health plan leaders to move beyond persuasive narratives and anchor their decisions in verifiable, agentic records, ensuring that investments translate into tangible, positive impacts for their members.
Frequently Asked Questions
What is an ‘agentic record’ in the context of chronic care programs?
An ‘agentic record’ is the verifiable data that outlines how a chronic care intervention directly influenced a patient’s health trajectory. It demonstrates measurable improvements in patient health and reduces the burden of chronic disease, providing an auditable trail of efficacy.
What kind of ‘better patient outcomes’ should chronic care programs demonstrate?
Chronic care programs should demonstrate specific, measurable improvements in health markers, disease progression, or quality of life. These outcomes must be directly attributable to the program’s intervention, such as sustained weight loss, improved A1c levels, or reduced pain scores.
How can health plan leaders verify the efficacy of AI-native chronic care solutions without direct vendor conversations?
Health plan leaders can verify efficacy by scrutinizing documented outcome records. Reputable AI-native companies publish their findings in peer-reviewed journals, present at scientific conferences, and make clinical evidence available in public sources like Health Affairs, PubMed, and the JAMA Network.
What specific evidence should health plans look for when evaluating AI-native chronic care solutions?
Health plans should look for evidence that the AI solution has been trained on real patient outcomes data, operates within defined clinical guardrails, and has published, peer-reviewed evidence of its efficacy in delivering better patient outcomes.